choline positron emission tomography ( [C-11] choline PET) has been expected to be one of the new PET modalities similar to [F-18] fuluorodeoxyglucose positron emission tomography (FDG-PET), which has spread worldwide as a gold standard of PET oncologic imaging. However, there has been no report on [C-11] choline PET used for detection of colorectal cancer, which is one of major targets of oncologic FDG-PET. We initiated the research to investigate the detectability of [C-11] choline PET for various tumors including colorectal cancer. This is the first report of a patient who underwent surgical resection for advanced colon cancer depicted by [C-11] choline positron emission tomography/computed tomography.
INTRODUCTION
[C-11] choline positron emission tomography ([C-11] choline PET) has been expected as a new PET modality and reported to be useful for the detection of various tumors, such as brain tumor, lung cancer, esophageal cancer, prostate cancer, gynecological cancers, and bone and soft tissue sarcomas (1 -6) . We started the research in our institution on September 1, 2005 to clarify not only the detectability of [C-11] choline PET for various tumors but the mechanism of choline accumulation to cancer cells, which is approved by the Institutional Review Board. Here we report a successful detection of an advanced colon cancer by [C-11] choline PET, which seems to be the first case, and discuss the possibility of application of [C-11] choline PET to colorectal cancer.
CASE REPORT
A 50-year-old woman presented with melena and abdominal discomfort. The colonoscopy showed the elevated lesion in the sigmoid colon (Fig. 1) . From endoscopic findings this tumor was diagnosed as type 1 advanced colon cancer with invasion into the subserosa. Pathologic diagnosis by specimen of biopsy was well-differentiated adenocarcinoma. The computed tomography scan of the thorax, abdomen and pelvis revealed the thickening in the wall of the sigmoid colon and enlarged uterus suspected of leiomyoma. No specific enlarged lymph nodes and no definite metastases including the liver were detected. A whole body [C-11] choline positron emission tomography/computed tomography (PET/CT) was performed with the written informed consent to participate in this research approved by the Institutional Review Board. Emission scans from the skull to the mid thigh were obtained starting 14 min after intravenous injection of 444MBq of [C-11] choline, which was synthesized with a commercial module essentially using the method described by Hara and Yuasa (7). [C-11] choline PET images showed abnormal prominent uptake in the middle of the abdomen (Fig. 2a and c) . The maximal standardized uptake value (SUV) of this uptake was 6.97. This uptake was suspected to correspond to the sigmoid cancer. However, there was another strong accumulation close to this uptake, suspected to be physiological accumulation to the small intestine (Fig. 2c) . It was not so easy to differentiate between these uptakes only by PET images. Fused PET/CT images could show clearly that one prominent accumulation corresponded to the thickening in the wall of sigmoid colon in CT images (Fig. 2d ). Low abnormal uptake was observed in the pelvic space, which corresponded to myoma uteri. There was no other abnormal accumulation in [C-11] choline PET has been reported to be useful for the detection of various malignant tumors such as lung, esophageal and gynecological caners, and bone and soft sarcomas, as well as FDG-PET (1 -6). Furthermore, [C-11] choline PET is reported to be superior to FDG-PET in the detection of brain tumor and prostate cancer (1, 4) . Ramirez de Molina et al. reported that choline kinase, which catalyzes the phosphorylation of choline, is upregulated in lung, prostate and colorectal cancers (13) . Therefore, [C-11] choline is speculated to also detect colorectal cancer, which is one of the major targets of FDG-PET. However, there has been no report on [C-11] choline PET for detection of colorectal cancer. This is because it is generally accepted that [C-11] choline often accumulates in the small intestine and/or colon mucosa, in which cell turnover is very rapid. As a consequence, the various degrees of physiological uptake obscure accumulation to the tumor, which is similarly observed in FDG-PET (5). Hara reported that rectal cancer was visualized with [C-11] choline PET (14) . In our case, abnormal [C-11] choline deposit to the sigmoid colon could be detected, although there was physiological accumulation to the small intestine near the cancerous lesion. There was no other significant accumulation to the colon. In our experience, physiological colon uptake of [C-11] choline tends to be lower than accumulation in the small intestine, whereas physiological colon uptake of FDG is often so much higher than small intestine uptake that the cancerous lesion cannot be depicted. That might be an advantage of [C-11] choline PET in colorectal cancer. It might be due to the considerably rapid turnover of epitherial cells in the small intestine, but the precise reason is unknown, prompting further investigation. It is sometimes confusing whether abdominal uptake is corresponding to the small intestine or the colon on [C-11] choline PET images as well as on FDG-PET images. In such cases, fused PET/ CT images give great assistance in diagnosing correctly the location of abnormal uptake. Besides the detection of the primary site, staging is another important role of oncologic PET as an initial examination. There are some reports on [C-11] choline PET as a staging procedure for prostate cancer and bone and soft tissue sarcomas (15, 16) . In our case, lymph node metastases could not be detected by [C-11] choline PET. This was considered to be due to the 
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Colon cancer detected by carbon-11 choline PET/CT size of the lymph nodes (less than 10 mm in diameter). Hepatic metastasis, which is frequent in colon cancer, might be hardly depicted by [C-11] choline PET because [C-11] choline is observed physiologically in the liver. However, [C-11] choline PET might be useful for detecting other metastases of colorectal cancer such as brain metastasis, pulmonary metastasis and bone metastasis with low background uptake. In summary, here we described a case of advanced colon cancer. A whole body [C-11] choline PET/CT permitted detection of the primary site. However, further studies must be performed on staging, diagnosis for recurrence and evaluation for effect of treatment to confirm the usefulness of [C-11] choline PET for colorecatal cancer.
